NOVOCURE INC.

Lobbying for NOVOCURE INC.

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Pennsylvania · House · Senate · $110,000.00 expenses · posted Oct 13, 2025

Bills named in this filing 2

Lobbying activity 1

Medicare/Medicaid

General Medicare Issues. H.R.5343/S.1717 - Ensuring Patient Access to Critical Breakthrough Products Act of 2025.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.